Dianthus Therapeutics, Inc.
DNTH
Clasificación en acciones
#3909
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Precio por acción
$74.81
Capitalización bursátil
$4.18B
Cambio (1 día)
3.77%
Cambio (1 año)
109.85%
País
US
Comercio Dianthus Therapeutics, Inc. (DNTH)
Categoría
Healthcare
Ganancias de Dianthus Therapeutics, Inc. (DNTH)
Ganancias en Jun 2026 TTM: $-29.91M
Secondo gli ultimi rapporti finanziari di Dianthus Therapeutics, Inc., gli utili attuali della società sono $-29.91M. Nel 2023, la società ha registrato un utile di $-43.56M, una disminución en comparación con agli utili del 2022, che erano di $-28.48M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Dianthus Therapeutics, Inc. desde 2016 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $-29.91M | -64.80% |
| 2024 | $-84.97M | 95.08% |
| 2023 | $-43.56M | 52.95% |
| 2022 | $-28.48M | 117.22% |
| 2021 | $-13.11M | -82.51% |
| 2020 | $-74.94M | -2.39% |
| 2019 | $-76.77M | 33.48% |
| 2018 | $-57.52M | 62.06% |
| 2017 | $-35.49M | 276.32% |
| 2016 | $-9.43M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | -17,736.50% |
US
|
|
| $-3.09B | 10,221.31% |
US
|
|
| $-4.02B | 13,328.05% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -6,621.95% |
NL
|
